Antibiotic Overuse in Premature Low Birth Weight Infants in a Developing Country

by Maria S. Rueda, MD; Renzo Calderon-Anyosa, MD; Jorge Gonzales, MD; Christie G. Turin, MD; Alonso Zea-Vera, MD; Jaime Zegarra, MD; Sicilia Bellomo, MD; Luis Cam, MD; Anne Castaneda, MD; and Theresa J. Ochoa, MD, on behalf of the NEOLACTO Research Group

To be published in The Pediatric Infectious Disease Journal, March 2019. doi: 10.1097/INF.0000000000002055

 

Neonatal sepsis is a leading cause of child morbidity and mortality, especially in premature and low birth weight infants. Prompt antibiotic therapy is warranted, but its inappropriate use leads to bacterial resistance and adverse outcomes. This study aims to describe the antibiotic use for late-onset sepsis in Peruvian premature infants.

 

Continue reading
10 Hits
0 Comments

Inappropriate Antibiotic Prescribing for Acute Bronchitis in Children and Impact on Subsequent Episodes of Care and Treatment

by Jake R. Morgan, PhD; Kathleen M. Carey, PhD; Tamar F. Barlam, MD; Cindy L. Christiansen, PhD; and  Mari-Lynn Drainoni, PhD 

To be published in The Pediatric Infectious Disease Journal, March 2019. doi: 10.1097/INF.0000000000002117

 

 

This study aimed to examine whether inappropriate antibiotic treatment for an initial bout of acute bronchitis in childhood affects patterns of future healthcare utilization and antibiotic prescribing.

Continue reading
6 Hits
0 Comments

Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015

by Mahyar Etminan, PharmD; Michael Y. Guo, BSc; and Bruce Carleton, PharmD

To be published in The Pediatric Infectious Disease Journal, March 2019. doi: 10.1097/INF.0000000000002121

 

 

Fluoroquinolone (FQ) prescription rates have increased over the last 10 years despite recent warnings of serious adverse effects such as peripheral neuropathy and tendinopathy. Currently, there are no published data on the extent or appropriateness of FQ prescribing in children.

Continue reading
8 Hits
0 Comments

Omadacycline for Community-Acquired Bacterial Pneumonia

by Roman Stets, M.D., Ph.D., Monica Popescu, M.D., Joven R. Gonong, M.D., Ismail Mitha, M.D., William Nseir, M.D., Andrzej Madej, M.D., Ph.D., Courtney Kirsch, B.S., Anita F. Das, Ph.D., Lynne Garrity-Ryan, Ph.D., Judith N. Steenbergen, Ph.D., Amy Manley, B.S., Paul B. Eckburg, M.D., Evan Tzanis, B.S., Paul C. McGovern, M.D., and Evan Loh, M.D.

Published in The New England Journal of Medicine, 07 February 2019. DOI: 10.1056/NEJMoa1800201 

 

 

Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community-acquired bacterial pneumonia.

Continue reading
15 Hits
0 Comments

Current antimicrobial management of community-acquired pneumonia in HIV-infected children

by Nuttall JJC

Published in Expert Opinion on Pharmacotherapy, 21 January 2019.

 

Community-acquired pneumonia is a leading cause of morbidity and mortality amongst HIV-infected infants and children. Polymicrobial infection is common and, due to the difficulties in confirming the etiology of pneumonia, empiric broad-spectrum antimicrobial therapy is frequently used.

 

Continue reading
18 Hits
0 Comments